Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824145 · ClinicalTrials.gov registry record · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
A NA study of Metastatic Breast Cancer, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- NA
- Development phase
- 176
- Enrollment target
- 2
- Study locations
NCT03824145: Recruiting NA study of Metastatic Breast Cancer, sponsored by Medical College of Wisconsin.
NCT03824145 is a NA study of Metastatic Breast Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 176 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (14% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03824145, a NA study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- NA
- Development phase
- 176 participants
- Enrollment target
- 2
- Study locations
Study Summary
This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).
Primary Outcome
Number of lifestyle coaching sessions completed out of a possible total of 16 sessions
Conditions Studied
Interventions
- BEHAVIORAL Attention Control
- BEHAVIORAL Lifestyle Intervention
Study Locations (2)
Illinois
- Loyola University - Maywood
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2027-02-01 |
| Phase | NA |
What NCT03824145 shows while recruiting
NCT03824145 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Attention Control is the first listed.
NCT03824145 reports a single indexed study location in Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03824145 about?
NCT03824145 is a clinical study titled "Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer". This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).
What is the current status of trial NCT03824145?
This trial is currently recruiting. It is a NA study. The enrollment target is 176 participants. The study started on 2022-11-01. Estimated completion is 2027-02-01.
What conditions does trial NCT03824145 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT03824145?
The interventions under investigation include: Attention Control (BEHAVIORAL), Lifestyle Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03824145?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03824145 being conducted?
This trial has 2 study locations across Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03824145's enrollment target sits among peer trials
176 36th of 139 higher than 103 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Adaptation of a Values Assessment Tool
RECRUITING · NA
-
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
RECRUITING · NA
-
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
RECRUITING · NA
-
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
RECRUITING · NA
-
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
- NCT04359069 · 176 participants · NA
Duration of Urinary Catheterization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI